TNFRSF1B and synovial sarcoma: As expected, we observed a dose-dependent proliferation of Teff at low concentrations of TNFR2 antagonist (0.1–12.5 μg/ml) in both SS patients and controls (Fig. 5a, b and Supplementary File S7a).